{
    "clinical_study": {
        "@rank": "80788", 
        "arm_group": {
            "arm_group_label": "Single arm", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "A Phase I study to Assess the Safety, Tolerability of Tremelimumab in Japanese Patients with\n      Advanced Solid Malignancies"
        }, 
        "brief_title": "A Phase I Study to Assess the Safety, Tolerability of Tremelimumab in Japanese Patients With Advanced Solid Malignancies", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Malignancies", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "To investigate the safety and tolerability of tremelimumab when given to Japanese patients\n      with advanced solid malignancies and define the dose(s) for further clinical evaluation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Japanese aged at least 20 years old at a time of enrollement.\n\n          2. Histological or cytological confirmation of a solid malignant tumor excluding\n             lymphoma that is refractory to standard therapies or for which no standard therapies\n             exist.\n\n          3. Eastern Co-operative Oncology group (ECOG) Performance Status (PS) 0-1 with no\n             deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks at a\n             time of randomization.\n\n          4. At least one lesion (measurable and/or non-measurable) that can be accurately\n             assessed at baseline by computerised tomography (CT), magnetic resonance imaging\n             (MRI) or plain X-ray and is suitable for repeated assessment.\n\n          5. Adequate bone marrow, hepatic, and renal function\n\n          6. Willingness to provide consent for archival biopsy samples if available.\n\n        Exclusion Criteria:\n\n          1. Received any prior treatment with monoclonal antibody against Programmed death 1\n             (PD1), Programmed death ligand 1 (PD-L1) and CTLA-4 (eg, ipilimumab)\n\n          2. The last dose of prior chemotherapy or radiation therapy was received less than 2\n             weeks prior to randomization 3 Currently receiving systemic corticosteroids or other\n             immunosuppressive medications or has a medical condition that requires the chronic\n             use of corticosteroids.\n\n        4. Receipt of live attenuated vaccination within 28 days of starting tremelimumab\n        treatment 5. Active, untreated central nervous system (CNS) metastasis (subjects with\n        brain metastases who are identified at screening 6. History of other malignancy unless the\n        subject has been disease-free for at least 3 years.\n\n        7. Any unresolved chronic toxicity CTCAE grade \u22652 from previous anti-cancer therapy at the\n        time of randomization, 8. Major surgical procedure within 30 days of starting"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141347", 
            "org_study_id": "D4880C00010"
        }, 
        "intervention": {
            "arm_group_label": "Single arm", 
            "description": "Tremelimumab administered intravenously", 
            "intervention_name": "Tremelimumab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sapporo-shi", 
                    "country": "Japan"
                }, 
                "name": "Research Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Tremelimumab in Japanese Patients With Advanced Solid Malignancies", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Akemi Komura, Master of Science", 
            "phone": "81-3-6268-2740"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To investigate the safety and tolerability of tremelimumab when given to Japanese patients with advanced solid malignancies and define the dose(s) for further clinical evaluation.", 
            "measure": "Advers event", 
            "safety_issue": "Yes", 
            "time_frame": "up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141347"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}